AbbVie settles Humira patent litigation, keeping U.S. 'monopoly prices'

AbbVie settles Humira patent litigation, keeping U.S. 'monopoly prices'

STAT Plus: AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

By ED SILVERMAN

KRISTOFFER TRIPPLAAR/SIPA/AP

AbbVie settled patent litigation with Boehringer Ingelheim, which can sell a biosimilar version of Humira as part of the deal — but not until July 2023.

READ MORE